GWN Securities’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$943K Buy
15,543
+405
+3% +$23.6K 0.18% 140
2025
Q4
$817K Buy
15,138
+973
+7% +$46.8K 0.17% 148
2025
Q3
$641K Buy
14,165
+4,399
+45% +$205K 0.15% 159
2025
Q2
$453K Sell
9,766
-65,854
-87% -$3.23M 0.08% 225
2025
Q1
$3.43M Buy
75,620
+65,917
+679% +$3.84M 0.19% 136
2024
Q4
$576K Buy
+9,703
New +$542K 0.15% 136

Other funds holding BMY

GWN Securities's BMY Position: Q1 2026 in Review

GWN Securities increased its Bristol-Myers Squibb (BMY) stake by 2.7% in Q1 2026, buying an estimated $23.6K and bringing the position to 15,543 shares worth $943K. The position accounts for 0.18% of the portfolio, ranked #140.

GWN Securities first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.43M in Q1 2025. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • GWN Securities held 15,543 shares of Bristol-Myers Squibb worth $943K as of Q1 2026.
  • GWN Securities bought 405 Bristol-Myers Squibb shares in Q1 2026, an estimated $23.6K.
  • Bristol-Myers Squibb made up 0.18% of GWN Securities's portfolio in Q1 2026, its #140 holding.
  • GWN Securities first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
  • GWN Securities's Bristol-Myers Squibb position peaked at $3.43M in Q1 2025.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on GWN Securities's 13F filing for Q1 2026, filed 15 May 2026.